Drug in new class of targeted therapies shows early promise against blood-related cancers
Thursday, May 20, 2010 - 00:31
in Health & Medicine
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia.